Peter Andersen, SVP of infectious disease at the Novo Nordisk Foundation
December 18, 2023 08:28 AM ESTUpdated December 19, 07:00 AM
R&D
Manufacturing

No­vo Nordisk Foun­da­tion to launch $260M vac­cine ini­tia­tive in ear­ly 2024

Anna Brown

News Reporter

The No­vo Nordisk Foun­da­tion, which op­er­ates in­de­pen­dent­ly from the phar­ma com­pa­ny, is pump­ing DKK 1.8 bil­lion ($260 mil­lion) to launch an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

FDA ap­proves Io­n­is’ treat­ment for a rare meta­bol­ic dis­or­der

A service from the Financial Times